The patents for some of these multi-billion dollar-worth drugs are expiring in the (very) near future. Humira, AbbVie’s highest selling drug, already faces the launch of several biosimilar versions. Its main patent was originally due for expiry 2018 in the EU and 2023 in the States, although it is a complex legal situation.
Aflibercept patents, held by Regeneron/Bayer, expire between 2023 and 2032 in the US and multiple companies have already filed (or are planning to file) for regulatory approval in the race for the first Eylea biosimilar.
Got any tips for the next high profile, highly profitable target?
Figure 1 depicts a number of blockbuster drugs, including humanized antibody therapies, kinase inhibitors and hormonal-based biotherapies with upcoming patent expiry dates which are likely being targeted for biosimilar development.